• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    AddLife (OM:ALIF B) Has Investors Asking A Bigger Question

    Simply Wall St·10/24/2026 03:37:33
    语音播报

    AddLife (OM:ALIF B) is back in focus after reporting third quarter 2026 earnings, with higher sales, stronger net income and improved earnings per share, alongside management commentary on organic growth and cash flow.

    AddLife’s recent earnings update arrives after a strong run in the share price, with a 30 day share price return of 7.91% and a 90 day gain of 16.95%. Over the same time, the 1 year total shareholder return has declined 10%, while the 3 year total shareholder return is very large. This points to momentum that has been rebuilt more recently than it has over the longer term.

    Scan other healthcare distributors showing similar earnings momentum and pricing resets with the hand picked 192 high quality undervalued stocks.

    Bulls point to AddLife’s earnings momentum and cash generation, while bears focus on the rich multiples and prior share price swings. Which side does the current valuation actually support as you weigh the recent move?

    Most Popular Narrative: 10% Undervalued

    The most followed narrative puts AddLife’s fair value at SEK204.75 per share, compared with the latest close at SEK184.20, which frames the recent share price recovery as only a partial catch up to that estimate.

    AddLife is prioritizing organic growth and profitability improvements through initiatives such as optimizing their product portfolio by removing less profitable products, which is expected to enhance gross margins and overall earnings. The company plans to leverage its strengthened balance sheet to accelerate acquisition activity, particularly in high-margin and fast-growing segments like orthopedic surgery, which could drive future revenue growth and increase EBITA margins.

    See why 3 investors see AddLife as 10% undervalued.

    Analysts behind this narrative apply a 6.65% discount rate and arrive at a SEK204.75 fair value, which implies the stock is about 10% below that assessment at current levels. The framework leans heavily on assumptions for revenue growth of 8.3% a year, a profit margin near 6.1%, and a future P/E multiple of roughly 36.7x that sits slightly above the current industry figure cited in the narrative. Readers should treat those inputs as scenario building blocks rather than fixed outcomes, and test whether such growth, profitability and valuation multiples feel reasonable for a healthcare distributor with SEK10.7b in sales and SEK644m in net income.

    Result: Fair Value of SEK204.75 (UNDERVALUED)

    Still, if funding for academic research stays muted or if supply chain issues intensify, the upbeat AddLife narrative could quickly look too optimistic.

    Find out about the key risks to this AddLife narrative.

    Next Steps

    Uncertain whether the AddLife story is currently more about risk or reward? Move quickly from reading to testing that view against the 3 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond AddLife?

    If you stop with AddLife, you miss a much wider opportunity set. Put a few more quality candidates on your radar while this research is fresh.